Highlights of This Issue 553

REVIEW

555 New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer
Sucharita J. Mistry and William K. Oh

CHEMICAL THERAPEUTICS

567 A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Hidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, Jennifer Bishop, Francois Lameureux, Christian Thomas, David Briere, Gerrit Los, Martin Gleave, Andrea Fanjul, and Amina Zoubedi

577 Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus, Srdan Verstovsek, Taghi Manshouri, Jacqueline E. Smith, Karissa Peth, Sunil Abhyankar, Joseph McGuirk, and Kapil N. Bhalla

589 Afinatib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Takashi Ninomiya, Nagio Takigawa, Eiki Ichihara, Nobuaki Ochi, Toshi Murakami, Yoshihiro Honda, Toshio Kubo, Daisuke Minami, Kenichiro Kudo, Mitsune Tanimoto, and Katsuyuki Kiura

598 Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth
Sivapriya Ponnurangam, David Standing, Parthasarathy Ranjarajan, and Dharmalingam Subramaniam

610 Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents
Heng Yang, Christie E. Pinello, Jian Luo, Dawei Li, Yunfei Wang, Lisa Y. Zhao, Stephan C. Jahn, Sanjay Adrian Saldanha, Jamie Planck, Kyla R. Geary, Haiching Ma, Brian K. Law, William R. Roush, Peter Hodder, and Daiqing Liao

SMALL MOLECULE THERAPEUTICS

621 Spongian Diterpenoids Inhibit Androgen Receptor Activity
Yu Chi Yang, Labros G. Meimetis, Amy H. Tien, Nasrin R. Mawji, Gavin Carr, Jun Wang, Raymond J. Andersen, and Marianne D. Sadar

632 Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells

643 Regression of Lung Cancer by Hypoxia-Sensitizing Ruthenium Polypyridyl Complexes
Abhishek Yadav, Thamaraj Anarathane, Arthi Krishnan, Sharad S. Singhal, Sushma Yadav, Adam S. Dayoub, Doyle L. Hawkins, Sanjay Awasthi, and Frederick M. MacDonnell

644 Designing and Developing S100P Inhibitor S-Methyl Cromolyn for Pancreatic Cancer Therapy
Thiruvengadham Arumugam, Vijaya Ramachandran, Duoli Sun, Zhenghong Peng, Ashutosh Pal, David S. Maxwell, William G. Bornmann, and Craig D. Logsdon

663 A Novel Sulindac Derivative Inhibits Lung Adenocarcinoma Cell Growth through Suppression of Akt/mTOR Signaling and Induction of Autophagy
Evrim Gurpinar, William E. Grizzle, John J. Shacka, Burton J. Mader, Nan Li, Nicholas A. Piazza, Suzanne Russo, Adam B. Keeton, and Gary A. Piazza

Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Nicholas G. Nickols, Jerzy O. Szablowski, Amanda E. Hargrove, Benjamin C. Li, Jevgenij A. Raskatov, and Peter B. Dervan
### LARGE MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>685</td>
<td>A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth</td>
<td>Emily Fontenot, Emma Rossi, Russell Mumper, Stephanie Snyder, Sharareh Siamakpour-Reihani, Ping Ma, Eleanor Hilliard, Bradley Bone, David Ketelsen, Charlene Santos, Cam Patterson, and Nancy Klauber-DeMore</td>
</tr>
<tr>
<td>759</td>
<td>Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma</td>
<td>Zebin Wang, Yu Zheng, Hyun Jung Park, Jing Li, Janai R. Carr, Yi-ju Chen, Megan M. Kiefer, Dragana Kopanja, Srilata Bagchi, Angela L. Tyner, and Pradip Raychaudhuri</td>
</tr>
</tbody>
</table>

### CANCER THERAPEUTICS INSIGHTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>696</td>
<td>ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK</td>
<td>Yunguang Sun, Kamila A. Nowak, Nicholas G. Zaorsky, Chia-Lin Winchester, Kunal Dalal, Nicholas J. Giacalone, Ningbo Liu, Maria Werner-Wasik, Mariusz A. Wasik, Adam P. Dicker, and Bo Lu</td>
</tr>
<tr>
<td>777</td>
<td>Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells</td>
<td>Xingnan Zheng, Kan He, Lin Zhang, and Jian Yu</td>
</tr>
</tbody>
</table>

### TOOLS & TECHNOLOGIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>819</td>
<td>[18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941</td>
<td>Christopher Cawthorne, Natalie Burrows, Roben G. Gieling, Christopher J. Morrow, Duncan Forster, Jamil Gregory, Marc Radigois, Alison Snigova, Muhammad Babur, Kathryn Simpson, Cassandra Hodkinson, Gavin Brown, Adam McMahon, Caroline Dive, Duncan Hiscock, Ian Wilson, and Kaye J. Williams</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Mitochondria is the powerhouse of cells (structure, green), supplying the majority of ATP that is essential for cell survival. However, cancer cells present a distinct glycolytic metabolism profile (Warburg effect), which is linked to the malignant transformation process. The emerging anti-VEGF therapy fights cancers by starving the energy supplement, but it was found to enhance the Warburg effect and induce even more aggressive phenotypes. Cancer cells with acquired resistance to anti-VEGF therapy display impaired mitochondria structure and hyperactive glycolytic metabolism, which render them vulnerable to glycolysis blockade therapy. For details, see article by Xu and colleagues on page 717.
Molecular Cancer Therapeutics

12 (5)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/12/5

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.